GlassScriptPhysician profile
Derek J Hirschman
NPI 1285016303
$17,026.79
in general payments reported to CMS, 2019-2025
40 companies · $3,541 in 2025
The $3,541 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,263 · 2020: $753 · 2021: $2,002 · 2022: $2,600 · 2023: $2,582 · 2024: $3,285 · 2025: $3,541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,793 · Education: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,792.70 |
| Education | $557.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,693.50 | 2019-2025 | |
| Janssen Biotech, INC. | $1,956.51 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $1,792.86 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,562.18 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Genzyme Corporation | $1,103.11 | 2019-2025 | |
| Ucb, INC. | $731.80 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $721.52 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $663.69 | 2019-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $630.08 | 2019-2025 | Nemluvio, Aklief, Oracea |
| E.R. Squibb & Sons, L.L.C. | $577.89 | 2022-2025 | Sotyktu |
| Incyte Corporation | $532.48 | 2022-2025 | Opzelura |
| Pfizer INC. | $471.01 | 2019-2025 | |
| Lilly USA, LLC | $451.48 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $356.58 | 2019-2024 | Cabtreo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.84 | 2022-2025 | Spevigo |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $340.19 | 2020-2025 | Adbry, Anzupgo |
| Organogenesis INC. | $304.22 | 2023-2025 | Puraply Wound Matrix, Cygnus Dual, Simplimax |
| Celgene Corporation | $276.63 | 2019 | |
| Mayne Pharma Commercial LLC | $250.53 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $172.86 | 2021 | |
| Arcutis Biotherapeutics, INC. | $95.99 | 2023-2024 | Zoryve |
| Genentech USA, INC. | $90.02 | 2020-2023 | Xolair |
| Dermavant Sciences, INC. | $83.13 | 2023-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $81.85 | 2022 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Allergan, INC. | $79.89 | 2022 | |
| Smith+Nephew, INC. | $72.46 | 2023-2024 | Collagenase Santyl, Grafix Pl |
| Almirall LLC | $61.70 | 2019-2021 | |
| Journey Medical Corporation | $58.22 | 2024-2025 | |
| Strata Skin Sciences, INC. | $53.49 | 2021-2025 | Xtrac |
| Verrica Pharmaceuticals INC. | $52.39 | 2023-2024 | Ycanth |
| Biofrontera INC. | $33.79 | 2021 | |
| Kerecis Limited | $32.20 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Convatec INC. | $28.72 | 2025 | |
| Surgenex LLC | $26.17 | 2025 | Ardeograft, Pellograft, Surmatrix |
| Lnhc, INC | $23.68 | 2025 | Zelsuvmi |
| Mimedx Group, INC. | $22.31 | 2025 | |
| Botanix Sb INC | $18.75 | 2025 | Sofdra |
| Dermira, INC. | $16.24 | 2020 | |
| Prugen, INC. Pharmaceuticals | $11.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Hirschman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.